

Sigma Healthcare 10% strategic shareholding now complete

Pharmx Technologies Limited (ASX: PHX) (**Pharmx** or the **Company**) refers to its announcement on 23 February 2026 regarding the multi-year strategic alliance with Sigma Healthcare Limited (**Sigma**), under which Sigma agreed to subscribe for shares representing a 10% interest in Pharmx and was provided a seat on the Pharmx Board.

Following completion of Sigma's initial subscription for 59,950,679 shares, Sigma currently holds approximately 9.1% of Pharmx on a post-issue basis. Pharmx and Sigma have agreed that Sigma will subscribe for and Pharmx will issue an additional 6,661,187 ordinary shares to Sigma, which will take its holding to 10% of Pharmx's issued capital as originally contemplated by the Strategic Alliance Agreement (**Agreement**).

The additional shares, which will be issued at the same price per share (\$0.145) as Sigma's original subscription under the Agreement, will be issued within the Company's existing placement capacity under Listing Rule 7.1. There is no change to any other term of the Agreement.

ENDS

This announcement was authorised for release by the Board of Pharmx Technologies Limited.

For further information, contact:

Tom Culver
Chief Executive Officer
investor.relations@pharmx.com.au



About Pharmx Technologies Limited

Pharmx is ANZ's leading pharmacy ordering platform, providing essential technology infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately \$20 billion in transactions annually through its robust, high-availability platform, driving efficient operations, seamless connectivity, and valuable insights across its ordering, eInvoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.

investor.relations@pharmx.com.au
PO Box Q281 Queen Victoria
Building, Sydney, NSW 1230

pharmx.com.au
1300 724 579
ABN: 25 000 091 305
ACN: 000 091 305